Subscribe
istock-629794242xesai-1
Xesai / iStockphoto.com
19 October 2018Americas

Amgen injects £50m in UK gene-sequencing company

Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.
Europe
Oxford Nanopore signs CRISPR licence
20 September 2019   UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.
Europe
Oxford Nanopore signs CRISPR licence
20 September 2019   UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.

More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Pacific Biosciences and Oxford Nanopore settle patent claims
9 May 2018   US-based Pacific Biosciences has entered into a five-year settlement agreement with Oxford Nanopore after the companies were locked in a legal battle.
Europe
Oxford Nanopore signs CRISPR licence
20 September 2019   UK-based Oxford Nanopore has obtained a licence to CRISPR-Cas9 IP for nanopore sequencing, a third-generation approach used in the sequencing of biopolymers.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?